Shanghai's First CyberKnife(R) System Installed at Major Academic Oncology Center

Install Marks the Fifth System in China and 121st CyberKnife System Installation

SUNNYVALE, Calif, Nov. 27 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Hua Shan Hospital in Shanghai has installed a CyberKnife(R) Robotic Radiosurgery System for its Pudong District facility. The installation marks the first CyberKnife System in Shanghai and the fifth System in China, providing greater patient access to the benefits of robotic radiosurgery.

"Hua Shan Hospital's reputation as a premier provider of health care in Shanghai and the surrounding region makes it a perfect location for the region's first CyberKnife System," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray Incorporated. "This installation is another step toward universal access to CyberKnife radiosurgery as a non-surgical option for cancer care."

The Hua Shan Hospital installation is the 121st CyberKnife installation to date. China's previous four CyberKnife Systems are located at Hong Kong Adventist Hospital in Hong Kong, Shandong LuTai Tumour Hospital in the Jinan Shandong Province, Tianjin Cancer Hospital in Tianjin, and Ruikang Hospital in Nanning, Guangxi province.

Hua Shan Hospital has been in partnership with Harvard Medical International since 2001 and serves as the primary teaching hospital of the Fudan University Medical School. Hua Shan Hospital has created a network of facilities to address the emerging needs of the country's people. The network currently includes Hua Shan Hospital in Shanghai's embassy district, Hua Shan Hospital in Pudong, and Nanchang Zhonghuan Hospital. The hospital's facility in Pudong serves as a center of excellence in oncology.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 100 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release regarding procedure growth and market acceptance, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward- looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-Q for the quarterly period ended September 29, 2007 and may be updated from time to time by our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated
11/27/2007
CONTACT: Susan Lehman of Rockpoint Public Relations, +1-510-832-6006,
susan@rockpointpr.com, for Accuray Incorporated; or Stephanie Tomei, Accuray
Public Relations Manager, +1-408-789-4234, stomei@accuray.com
Web site: http://www.accuray.com